Opthea (ASX:OPT) Tax Provision : A$13.31 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Opthea Tax Provision?

Opthea's tax provision for the six months ended in Dec. 2023 was A$7.53 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$13.31 Mil.

Opthea Tax Provision Historical Data

The historical data trend for Opthea's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Tax Provision Chart

Opthea Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Tax Provision

Get a 7-Day Free Trial

15.08

8.27

6.46

8.96

8.83

Opthea Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Tax Provision	Get a 7-Day Free Trial															4.08	4.81	3.03	5.78	7.53

Opthea Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$13.31 Mil.

Opthea (ASX:OPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.